Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2014
Reporting Period: Event-based report for January 7, 2014.
Key Financial Metrics
This filing is an event report and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the issuance of a third patent by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, the company's novel once-daily extended-release oxcarbazepine product.
Guidance, Outlook, and Risks
Management Commentary: The company announced the patent issuance via a press release (Exhibit 99.1).
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text beyond the standard context of intellectual property protection.
Investor Verification Checklist
- Verify the scope and expiration date of the third USPTO patent for Oxtellar XR.
- Review the full text of the press release (Exhibit 99.1) for additional strategic implications.
- Confirm the status of Oxtellar XR commercialization and market penetration.